Fiscal year 2024 executive and director compensation, incentive-plan design, equity activity, and governance — every figure in this brief is traceable to its exact location in the company’s SEC filing — the document, the section, the page, and the table, linked directly.
Each company listed discloses AVXL in its own benchmarking peer group, as disclosed in each company's most recent proxy statement within the last two proxy seasons. Two companies are therefore absent by design: one that named AVXL in an earlier year and no longer does, and one whose own most recent disclosure is older than the last two seasons.
| Named executive officer | Salary | Bonus | Stock awards | Option awards | Non-equity incentive | Pension / NQDC | All other | Total |
|---|---|---|---|---|---|---|---|---|
| Christopher Missling | $700,000 | $140,000 | $0 | $1,927,600 | $0 | $0 | $16,100 | $2,783,700 |
| President, Chief Executive Officer and Director | ||||||||
| Sandra Boenisch | 201,468 | 0 | 0 | 192,700 | 0 | 0 | 8,059 | 402,227 |
| Principal Financial Officer and Treasurer | ||||||||
A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.
| Named executive officer | FY2024 total | FY2023 total | FY2022 total | Δ FY2023→2024 |
|---|---|---|---|---|
| Christopher Missling | $2,783,700 | — | — | — |
| Sandra Boenisch | 402,227 | — | — | — |
Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.
Every insider equity transaction reported on Form 4 after the 2024 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.
| Insider | Role | Transaction date | Code | Shares | Price | Value | Security | Source |
|---|---|---|---|---|---|---|---|---|
| Christopher Missling | Director | 2025-04-28 | A | 125,000 | $0 | $0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2025-04-28 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steffen Thomas | Director | 2025-06-05 | D | 11,349 | 8 | 87,955 | Common | Form 4 ↗ |
| Steffen Thomas | Director | 2025-06-05 | D | 50,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Steffen Thomas | Director | 2025-06-05 | A | 50,000 | 2 | 88,000 | Common | Form 4 ↗ |
| Christopher Missling | Director | 2025-08-20 | A | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2025-08-20 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Missling | Director | 2025-09-11 | A | 187,500 | 5 | 945,000 | Common | Form 4 ↗ |
| Christopher Missling | Director | 2025-09-11 | D | 187,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Missling | Director | 2025-09-11 | D | 145,048 | 10 | 1,389,560 | Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2025-10-02 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Missling | Director | 2025-10-02 | A | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Sandra Boenisch | PFO & Treasurer | 2026-01-06 | A | 12,500 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
| Christopher Missling | Director | 2026-01-06 | A | 125,000 | 0 | 0 | Derivative, Class A Common | Form 4 ↗ |
Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.
| Executive | Award | Grant date | Threshold | Target | Granted | Maximum | Grant-date fair value |
|---|---|---|---|---|---|---|---|
| Sandra Boenisch | OPTION | 2024-02-20 | — | 50,000 | 50,000 | 50,000 | $192,700 |
| Christopher Missling | OPTION | 2024-02-20 | — | 500,000 | 500,000 | 500,000 | 1,927,600 |
| Named executive officer | Time-vested (RSU) | Performance-vested (PSU) | Options / SARs | % performance-vested |
|---|---|---|---|---|
| Sandra Boenisch | $0 | $0 | $192,700 | 0.0% |
| Christopher Missling | 0 | 0 | 1,927,600 | 0.0% |
% performance-vested = PSU grant-date fair value ÷ (RSU + PSU + Options), a computed value with the derivation shown in the register.
| Executive | Award | Shares unvested | Exercise price | Market value unvested |
|---|---|---|---|---|
| Christopher Missling | RSU | 375,000 | — | $900,000 |
| Sandra Boenisch | RSU | 50,000 | — | 120,000 |
| Sandra Boenisch | RSU | 30,000 | — | 72,000 |
| Sandra Boenisch | RSU | 40,000 | — | 96,000 |
| Christopher Missling | RSU | 500,000 | — | 1,200,000 |
We seek to compensate our named executive officers in a manner that is competitive, rewards performance that creates stockholder value, recognizes individual contributions, and encourages long-term value creation.
| CEO STI target (% of salary) | 20% |
|---|---|
| CEO LTI target (% of salary) | — |
| Independent consultant | — |
| Clawback policy | True |
| Anti-hedging | True |
| Anti-pledging | True |
| Meeting year | Meeting date | For | Against | Abstain | Support | Outcome |
|---|---|---|---|---|---|---|
| 2024 | 2024-06-18 | 28,406,111 | 4,728,255 | 759,625 | 83.81% | Passed |
| 2021 | 2021-05-25 | 29,900,319 | 3,212,520 | 826,667 | 88.1% | Passed |
| 2018 | 2018-04-17 | 9,907,130 | 2,958,367 | 237,974 | 77.01% | Passed |
Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year's compensation.
| Meeting year | Meeting date | Approval — company's computation |
|---|---|---|
| 2024 | 2024-06-18 | 83.81%a |
| 2021 | 2021-05-25 | 88.1%b |
| 2018 | 2018-04-17 | 77.01%c |
a. Approved under the standard stated in the filing — “Abstentions and broker non-votes, if any, will not be treated as votes cast and will have no impact on the proposal.”.
b. Approved under the standard stated in the filing — “Abstentions will be counted as votes present and entitled to vote on the proposals considered at the Annual Meeting and, therefore, will have the effect of votes against Proposals 2, 3, 4 and 5.”.
c. Voting standard not stated in the filing.
Approval percentages are the company's own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.
| Director | Cash fees | Stock awards | Option awards | Non-equity incentive | All other | Total |
|---|---|---|---|---|---|---|
| Jiong MaIndependent · Board Chair · Audit · Nominating/Governance | $41,000 | $0 | $202,200 | $0 | $0 | $243,200 |
| Claus van der VeldenIndependent · Audit (Chair) · Compensation (Chair) · Nominating/Governance (Chair) | 41,000 | 0 | 202,200 | 0 | 0 | 243,200 |
| Athanasios SkarpelosIndependent | 25,000 | 0 | 202,200 | 0 | 0 | 227,200 |
| Steffen ThomasIndependent · Audit · Compensation · Nominating/Governance | 25,000 | 0 | 202,200 | 0 | 0 | 227,200 |
| Peter DonhauserIndependent · Compensation · Nominating/Governance | 25,000 | 0 | 202,200 | 0 | 0 | 227,200 |
| Christopher MisslingEmployee director | 0 | 0 | 0 | — | 0 | 0 |
| Annual cash retainer | $25,000 |
|---|---|
| Annual equity retainer | $202,200 |
| Per board meeting fee | — |
| Committee chair fees (audit / comp / nom-gov) | — |
| Stock ownership guideline | — |
| Component | FY2024 |
|---|---|
| Cash retainers and fees | $157,000 |
| Equity awards (grant-date value) | $0 |
| All other compensation | $0 |
| Total cost of the board | $157,000 |
Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.
Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company's own proxy statement.
| Rank | Company | FY | Chief executive | Salary | Stock awards | Option awards | Non-equity incentive | Total |
|---|---|---|---|---|---|---|---|---|
| 1 | Anavex Life Sciences | 2024 | Christopher Missling | $700,000 | $0 | $1,927,600 | $0 | $2,783,700 |
Each peer's compensation is from its most recently filed proxy; fiscal years differ by company. Each peer's figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.
Each figure's location is given both for the eye (section · page · table · row · column) and for a script (table/row/column index and exact character span in the filed document). Any figure can be independently confirmed against the source.
| # | Supports | Document | Filed | Accession | Location in document |
|---|---|---|---|---|---|
| 1 | Section 01, Christopher Missling | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Summary Compensation”. As printed: 2,783,700. Filing ↗machine: r1 · c23 · span 229348–229357 |
| 2 | Section 01, Sandra Boenisch | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Summary Compensation”. As printed: 402,227. Filing ↗machine: r4 · c23 · span 232496–232503 |
| 3 | Section 03, Sandra Boenisch OPTION | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “EXECUTIVE AND DIRECTOR COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t30 · r4 · c15 · span 232214–232221 |
| 4 | Section 03, Christopher Missling OPTION | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “EXECUTIVE AND DIRECTOR COMPENSATION &” · grants of plan-based awards table. Filing ↗machine: t30 · r1 · c15 · span 228961–228970 |
| 5 | Section 08, Jiong Ma | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 243,200. Filing ↗machine: span 314724–314731 |
| 6 | Section 08, Claus van der Velden | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 243,200. Filing ↗machine: span 315902–315909 |
| 7 | Section 08, Athanasios Skarpelos | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 227,200. Filing ↗machine: span 317080–317087 |
| 8 | Section 08, Steffen Thomas | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 227,200. Filing ↗machine: span 318241–318248 |
| 9 | Section 08, Peter Donhauser | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 227,200. Filing ↗machine: span 319414–319421 |
| 10 | Section 08, Christopher Missling | DEF 14A | 2025-04-25 | 0001731122-25-000607 | Section “Director Compensation”. As printed: 0. Filing ↗ |
| 11 | Section 02, Christopher Missling 2025-04-28 | Form 4 | 2025-04-30 | 0001731122-25-000654 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 12 | Section 02, Sandra Boenisch 2025-04-28 | Form 4 | 2025-04-30 | 0001731122-25-000655 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 13 | Section 02, Steffen Thomas 2025-06-05 | Form 4 | 2025-06-09 | 0001731122-25-000837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 14 | Section 02, Steffen Thomas 2025-06-05 | Form 4 | 2025-06-09 | 0001731122-25-000837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 15 | Section 02, Steffen Thomas 2025-06-05 | Form 4 | 2025-06-09 | 0001731122-25-000837 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 16 | Section 02, Christopher Missling 2025-08-20 | Form 4 | 2025-08-22 | 0001731122-25-001167 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 17 | Section 02, Sandra Boenisch 2025-08-20 | Form 4 | 2025-08-22 | 0001731122-25-001168 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 18 | Section 02, Christopher Missling 2025-09-11 | Form 4 | 2025-09-12 | 0001731122-25-001246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 19 | Section 02, Christopher Missling 2025-09-11 | Form 4 | 2025-09-12 | 0001731122-25-001246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 20 | Section 02, Christopher Missling 2025-09-11 | Form 4 | 2025-09-12 | 0001731122-25-001246 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 21 | Section 02, Sandra Boenisch 2025-10-02 | Form 4 | 2025-10-03 | 0001731122-25-001355 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 22 | Section 02, Christopher Missling 2025-10-02 | Form 4 | 2025-10-03 | 0001731122-25-001354 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 23 | Section 02, Sandra Boenisch 2026-01-06 | Form 4 | 2026-01-09 | 0001731122-26-000035 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 24 | Section 02, Christopher Missling 2026-01-06 | Form 4 | 2026-01-09 | 0001731122-26-000036 | Insider equity transaction reported since the proxy statement. Filing ↗ |
| 25 | Section 06, 2024 vote | Form 8-K | 2024-06-21 | 0001731122-24-001003 | Item 5.07 · say-on-pay result. As reported: 83.81% (votes for as printed: 28,406,111). Filing ↗ |
| 26 | Section 06, 2021 vote | Form 8-K | 2021-05-28 | 0001731122-21-000974 | Item 5.07 · say-on-pay result. As reported: 88.1%. Filing ↗ |
| 27 | Section 06, 2018 vote | Form 8-K | 2018-04-20 | 0001615774-18-002786 | Item 5.07 · say-on-pay result. As reported: 77.01%. Filing ↗ |
| 28 | Section 03b vehicle mix (computed) | Computed | — | computed | RSU / PSU / Options grant-date fair values summed per officer from the grants table; % performance-vested = PSU ÷ (RSU+PSU+Options).machine: formula: sums + PSU ratio |
| 29 | Section 09b board cost (computed) | Computed | — | computed | Cash 157,000 + equity 0 + all other 0 = 157,000, summed across the director compensation table rows.machine: formula: Σ = 157,000 |
| 30 | Anavex Life Sciences (subject), Section 10b CEO total | DEF 14A | 2025-04-25 | 0001731122-25-000607 | CEO total compensation as printed in Anavex Life Sciences's own proxy. As printed: 2,783,700. Filing ↗machine: r1 · c23 · span 229348–229357 |